Korean J Gastroenterol.  2024 Nov;84(5):215-222. 10.4166/kjg.2024.103.

Evaluation of Liver Fibrosis through Noninvasive Tests in Steatotic Liver Disease

• Cho Y

• KMID: 2561591
• DOI: http://doi.org/10.4166/kjg.2024.103

Abstract

Liver fibrosis, a critical predictor of the prognosis of metabolic dysfunction-associated steatotic liver disease (MASLD), is traditionally diagnosed via biopsy. Nevertheless, non-invasive alternatives, such as serum biomarkers, vibration-controlled transient elastography, and magnetic resonance elastography, have become prominent because of the limitations of biopsies. Serum biomarkers, such as fibrosis-4 index and NFS Score, are also used widely, offering reliable diagnostic performance for advanced fibrosis. Vibration-controlled transient elastography and shear wave elastography provide further non-invasive evaluations with high diagnostic accuracy, particularly for advanced fibrosis, but the results may be affected by factors such as obesity. Magnetic resonance elastography, with superior diagnostic accuracy and operator independence, is a promising method, but its high cost and limited availability restrict its widespread use. Emerging algorithms, such as NIS4, FAST, or MAST score, have strong potential in identifying high-risk metabolic dysfunction-associated steatohepatitis patients. The integration of multiple non-invasive methods can optimize diagnostic accuracy, reducing the need for invasive biopsies while identifying patients at risk of liver-related complications. Further research is needed to refine these diagnostic tools and improve accessibility.

Keyword

Steatotic liver disease; Noninvasive; Liver fibrosis

Reference

1. Ekstedt M, Hagström H, Nasr P, et al. 2015; Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 61:1547–1554. DOI: 10.1002/hep.27368. PMID: 25125077.

2. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. American Association for the Study of Liver Diseases. 2009; Liver biopsy. Hepatology. 49:1017–1044. DOI: 10.1002/hep.22742. PMID: 19243014.

3. Poynard T, Munteanu M, Imbert-Bismut F, et al. 2004; Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem. 50:1344–1355. DOI: 10.1373/clinchem.2004.032227. PMID: 15192028.

4. Ryan CK, Johnson LA, Germin BI, Marcos A. 2002; One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. Liver Transpl. 8:1114–1122. DOI: 10.1053/jlts.2002.36740. PMID: 12474149.

5. Wu J, You J, Yerian L, Shiba A, Schauer PR, Sessler DI. 2012; Prevalence of liver steatosis and fibrosis and the diagnostic accuracy of ultrasound in bariatric surgery patients. Obes Surg. 22:240–247. DOI: 10.1007/s11695-011-0509-8. PMID: 21901286.

6. Saadeh S, Younossi ZM, Remer EM, et al. 2002; The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 123:745–750. DOI: 10.1053/gast.2002.35354. PMID: 12198701.

7. Joo SK, Kim W, Kim D, et al. 2018; Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease. Liver Int. 38:331–341. DOI: 10.1111/liv.13549. PMID: 28796410.

8. Petta S, Wai-Sun Wong V, Bugianesi E, et al. 2019; Impact of obesity and alanine aminotransferase levels on the diagnostic accuracy for advanced liver fibrosis of noninvasive tools in patients with nonalcoholic fatty liver disease. Am J Gastroenterol. 114:916–928. DOI: 10.14309/ajg.0000000000000153. PMID: 31169533.

9. Sterling RK, Lissen E, Clumeck N, et al. 2006; Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 43:1317–1325. DOI: 10.1002/hep.21178. PMID: 16729309.

10. Imajo K, Kessoku T, Honda Y, et al. 2016; Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology. 150:626–637.e7. DOI: 10.1053/j.gastro.2015.11.048. PMID: 26677985.

11. Han S, Choi M, Lee B, et al. 2022; Accuracy of noninvasive scoring systems in assessing liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis. Gut Liver. 16:952–963. DOI: 10.5009/gnl210391. PMID: 35193993. PMCID: PMC9668505.

12. Mózes FE, Lee JA, Selvaraj EA, et al. 2022; Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut. 71:1006–1019. DOI: 10.1136/gutjnl-2021-324243. PMID: 34001645. PMCID: PMC8995830.

13. McPherson S, Hardy T, Dufour JF, et al. 2017; Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol. 112:740–751. DOI: 10.1038/ajg.2016.453. PMID: 27725647. PMCID: PMC5418560.

14. Angulo P, Hui JM, Marchesini G, et al. 2007; The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 45:846–854. DOI: 10.1002/hep.21496. PMID: 17393509.

15. Musso G, Gambino R, Cassader M, Pagano G. 2011; Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 43:617–649. DOI: 10.3109/07853890.2010.518623. PMID: 21039302.

16. Qureshi K, Clements RH, Abrams GA. 2008; The utility of the "NAFLD fibrosis score" in morbidly obese subjects with NAFLD. Obes Surg. 18:264–270. DOI: 10.1007/s11695-007-9295-8. PMID: 18214632.

17. Wong VW, Wong GL, Chim AM, et al. 2008; Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. Am J Gastroenterol. 103:1682–1688. DOI: 10.1111/j.1572-0241.2008.01933.x. PMID: 18616651.

18. Guha IN, Parkes J, Roderick P, et al. 2008; Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology. 47:455–460. DOI: 10.1002/hep.21984. PMID: 18038452.

19. Guturu P, Steffer K, Petersen JR, Snyder N. 2008; A new risk index for the estimation of fibrosis in non alcoholic fatty liver disease (NAFLD): comparison with the Mayo Score and the AST platelet ratio index (APRI). Hepatology. 48:522A.

20. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. 2008; Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 57:1441–1447. DOI: 10.1136/gut.2007.146019. PMID: 18390575.

21. Calès P, Lainé F, Boursier J, et al. 2009; Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol. 50:165–173. DOI: 10.1016/j.jhep.2008.07.035. PMID: 18977552.

22. Ruffillo G, Fassio E, Alvarez E, et al. 2011; Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease. J Hepatol. 54:160–163. DOI: 10.1016/j.jhep.2010.06.028. PMID: 20934232.

23. Parker R, Collins P, McCune A. 2009; Can clinical scoring systems replace liver biopsy in non-alcoholic fatty liver disease? J Hepatol. 51:189.

24. Wong VW, Vergniol J, Wong GL, et al. 2010; Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 51:454–462. DOI: 10.1002/hep.23312. PMID: 20101745.

25. Sumida Y, Yoneda M, Hyogo H, et al. 2011; A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol. 46:257–268. DOI: 10.1007/s00535-010-0305-6. PMID: 20842510.

26. Pimentel SK, Strobel R, Gonçalves CG, Sakamoto DG, Ivano FH, Coelho JC. 2010; Evaluation of the nonalcoholic fat liver disease fibrosis score for patients undergoing bariatric surgery. Arq Gastroenterol. 47:170–173. DOI: 10.1590/S0004-28032010000200010. PMID: 20721462.

27. Jun DW, Kim SG, Park SH, et al. 2017; External validation of the non-alcoholic fatty liver disease fibrosis score for assessing advanced fibrosis in Korean patients. J Gastroenterol Hepatol. 32:1094–1099. DOI: 10.1111/jgh.13648. PMID: 27859583.

28. Harrison SA, Ratziu V, Boursier J, et al. 2020; A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 5:970–985. DOI: 10.1016/S2468-1253(20)30252-1. PMID: 32763196.

29. Harrison SA, Ratziu V, Magnanensi J, et al. 2023; NIS2+™, an optimisation of the blood-based biomarker NIS4^® technology for the detection of at-risk NASH: A prospective derivation and validation study. J Hepatol. 79:758–767. DOI: 10.1016/j.jhep.2023.04.031. PMID: 37224923.

30. Koo BK, Joo SK, Kim D, et al. 2020; Development and validation of a scoring system, based on genetic and clinical factors, to determine risk of steatohepatitis in Asian patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 18:2592–2599.e10. DOI: 10.1016/j.cgh.2020.02.011. PMID: 32062042.

31. Xu K, Zheng KI, Zheng MH. 2021; External validation of the nonalcoholic steatohepatitis scoring system in patients with biopsy-proven nonalcoholic fatty liver disease in China. Clin Gastroenterol Hepatol. 19:412–413. DOI: 10.1016/j.cgh.2020.04.009. PMID: 33248101.

32. Lee G, You HJ, Bajaj JS, et al. 2020; Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD. Nat Commun. 11:4982. DOI: 10.1038/s41467-020-18754-5. PMID: 33020474. PMCID: PMC7536225.

33. Kwok R, Tse YK, Wong GL, et al. 2014; Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther. 39:254–269. DOI: 10.1111/apt.12569. PMID: 24308774.

34. Castéra L, Foucher J, Bernard PH, et al. 2010; Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology. 51:828–835. DOI: 10.1002/hep.23425. PMID: 20063276.

35. Vuppalanchi R, Siddiqui MS, Van Natta ML, et al. 2018; Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. Hepatology. 67:134–144. DOI: 10.1002/hep.29489. PMID: 28859228. PMCID: PMC5739967.

36. Wong VW, Vergniol J, Wong GL, et al. 2012; Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol. 107:1862–1871. DOI: 10.1038/ajg.2012.331. PMID: 23032979.

37. Naveau S, Lamouri K, Pourcher G, et al. 2014; The diagnostic accuracy of transient elastography for the diagnosis of liver fibrosis in bariatric surgery candidates with suspected NAFLD. Obes Surg. 24:1693–1701. DOI: 10.1007/s11695-014-1235-9. PMID: 24841950.

38. Wong VW, Irles M, Wong GL, et al. 2019; Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease. Gut. 68:2057–2064. DOI: 10.1136/gutjnl-2018-317334. PMID: 30658997.

39. Oeda S, Takahashi H, Imajo K, et al. 2020; Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan^® M/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: a multicenter prospective study. J Gastroenterol. 55:428–440. DOI: 10.1007/s00535-019-01635-0. PMID: 31654131.

40. Petta S, Maida M, Macaluso FS, et al. 2015; The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease. Hepatology. 62:1101–1110. DOI: 10.1002/hep.27844. PMID: 25991038.

41. Petta S, Wong VW, Cammà C, et al. 2017; Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. Hepatology. 65:1145–1155. DOI: 10.1002/hep.28843. PMID: 27639088.

42. Newsome PN, Sasso M, Deeks JJ, et al. 2020; FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 5:362–373. DOI: 10.1016/S2468-1253(19)30383-8. PMID: 32027858.

43. Sanyal AJ, Foucquier J, Younossi ZM, et al. 2023; Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores. J Hepatol. 78:247–259. DOI: 10.1016/j.jhep.2022.10.034. PMID: 36375686. PMCID: PMC10170177.

44. Pennisi G, Enea M, Falco V, et al. 2023; Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes. Hepatology. 78:195–211. DOI: 10.1097/HEP.0000000000000351. PMID: 36924031.

45. Karlas T, Dietrich A, Peter V, et al. 2015; Evaluation of transient elastography, acoustic radiation force impulse imaging (ARFI), and enhanced liver function (ELF) score for detection of fibrosis in morbidly obese patients. PLoS One. 10:e0141649. DOI: 10.1371/journal.pone.0141649. PMID: 26528818. PMCID: PMC4631322.

46. Liu H, Fu J, Hong R, Liu L, Li F. 2015; Acoustic radiation force impulse elastography for the non-invasive evaluation of hepatic fibrosis in non-alcoholic fatty liver disease patients: A systematic review & meta-analysis. PLoS One. 10:e0127782. DOI: 10.1371/journal.pone.0127782. PMID: 26131717. PMCID: PMC4489183.

47. Yoneda M, Suzuki K, Kato S, et al. 2010; Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. Radiology. 256:640–647. DOI: 10.1148/radiol.10091662. PMID: 20529989.

48. Bota S, Herkner H, Sporea I, et al. 2013; Meta-analysis: ARFI elastography versus transient elastography for the evaluation of liver fibrosis. Liver Int. 33:1138–1147. DOI: 10.1111/liv.12240. PMID: 23859217.

49. Selvaraj EA, Mózes FE, Jayaswal ANA, et al. 2021; Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. J Hepatol. 75:770–785. DOI: 10.1016/j.jhep.2021.04.044. PMID: 33991635.

50. Chimoriya R, Piya MK, Simmons D, Ahlenstiel G, Ho V. 2020; The use of two-dimensional shear wave elastography in people with obesity for the assessment of liver fibrosis in non-alcoholic fatty liver disease. J Clin Med. 10:95. DOI: 10.3390/jcm10010095. PMID: 33383965. PMCID: PMC7795317.

51. Chen J, Talwalkar JA, Yin M, Glaser KJ, Sanderson SO, Ehman RL. 2011; Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology. 259:749–756. DOI: 10.1148/radiol.11101942. PMID: 21460032. PMCID: PMC3099044.

52. Loomba R, Wolfson T, Ang B, et al. 2014; Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology. 60:1920–1928. DOI: 10.1002/hep.27362. PMID: 25103310. PMCID: PMC4245360.

53. Kim D, Kim WR, Talwalkar JA, Kim HJ, Ehman RL. 2013; Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography. Radiology. 268:411–419. DOI: 10.1148/radiol.13121193. PMID: 23564711. PMCID: PMC3721049.

54. Hsu C, Caussy C, Imajo K, et al. 2019; Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: A systematic review and pooled analysis of individual participants. Clin Gastroenterol Hepatol. 17:630–637.e8. DOI: 10.1016/j.cgh.2018.05.059. PMID: 29908362. PMCID: PMC6294709.

55. Park CC, Nguyen P, Hernandez C, et al. 2017; Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology. 152:598–607.e2. DOI: 10.1053/j.gastro.2016.10.026. PMID: 27911262. PMCID: PMC5285304.

56. Singh S, Venkatesh SK, Wang Z, et al. 2015; Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol. 13:440–451.e6. DOI: 10.1016/j.cgh.2014.09.046. PMID: 25305349. PMCID: PMC4333001.

57. Singh S, Venkatesh SK, Loomba R, et al. 2016; Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis. Eur Radiol. 26:1431–1440. DOI: 10.1007/s00330-015-3949-z. PMID: 26314479. PMCID: PMC5051267.

58. Ajmera V, Kim BK, Yang K, et al. 2022; Liver stiffness on magnetic resonance elastography and the MEFIB index and liver-related outcomes in nonalcoholic fatty liver disease: A systematic review and meta-analysis of individual participants. Gastroenterology. 163:1079–1089.e5. DOI: 10.1053/j.gastro.2022.06.073. PMID: 35788349. PMCID: PMC9509452.

59. Trout AT, Serai S, Mahley AD, et al. 2016; Liver Stiffness measurements with MR elastography: Agreement and repeatability across imaging systems, field strengths, and pulse sequences. Radiology. 281:793–804. DOI: 10.1148/radiol.2016160209. PMID: 27285061.

60. Shire NJ, Yin M, Chen J, et al. 2011; Test-retest repeatability of MR elastography for noninvasive liver fibrosis assessment in hepatitis C. J Magn Reson Imaging. 34:947–955. DOI: 10.1002/jmri.22716. PMID: 21751289. PMCID: PMC3176946.

61. Wang J, Glaser KJ, Zhang T, et al. 2018; Assessment of advanced hepatic MR elastography methods for susceptibility artifact suppression in clinical patients. J Magn Reson Imaging. 47:976–987. DOI: 10.1002/jmri.25818. PMID: 28801939. PMCID: PMC6729145.

62. Srinivasa Babu A, Wells ML, Teytelboym OM, et al. 2016; Elastography in chronic liver disease: Modalities, techniques, limitations, and future directions. Radiographics. 36:1987–2006. DOI: 10.1148/rg.2016160042. PMID: 27689833. PMCID: PMC5584553.

63. Noureddin M, Truong E, Gornbein JA, et al. 2022; MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis. J Hepatol. 76:781–787. DOI: 10.1016/j.jhep.2021.11.012. PMID: 34798176.

64. Jung J, Loomba RR, Imajo K, et al. 2021; MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. Gut. 70:1946–1953. DOI: 10.1136/gutjnl-2020-322976. PMID: 33214165. PMCID: PMC8131405.

65. Tamaki N, Imajo K, Sharpton S, et al. 2022; Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis. Hepatology. 75:661–672. DOI: 10.1002/hep.32145. PMID: 34496054. PMCID: PMC9683538.

66. Chen J, Yin M, Talwalkar JA, et al. 2017; Diagnostic performance of MR elastography and vibration-controlled transient elastography in the detection of hepatic fibrosis in patients with severe to morbid obesity. Radiology. 283:418–428. DOI: 10.1148/radiol.2016160685. PMID: 27861111. PMCID: PMC5395333.

67. Gordon SC, Kachru N, Parker E, Korrer S, Ozbay AB, Wong RJ. 2020; Health care use and costs among patients with nonalcoholic steatohepatitis with advanced fibrosis using the fibrosis-4 score. Hepatol Commun. 4:998–1011. DOI: 10.1002/hep4.1524. PMID: 32626832. PMCID: PMC7327220.

68. Vali Y, Lee J, Boursier J, et al. 2020; Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. J Hepatol. 73:252–262. DOI: 10.1016/j.jhep.2020.03.036. PMID: 32275982.

69. Lupsor M, Badea R, Stefanescu H, et al. 2010; Performance of unidimensional transient elastography in staging non-alcoholic steatohepatitis. J Gastrointestin Liver Dis. 19:53–60.

70. Gaia S, Carenzi S, Barilli AL, et al. 2011; Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. J Hepatol. 54:64–71. DOI: 10.1016/j.jhep.2010.06.022. PMID: 20932598.

71. Petta S, Di Marco V, Cammà C, Butera G, Cabibi D, Craxì A. 2011; Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. Aliment Pharmacol Ther. 33:1350–1360. DOI: 10.1111/j.1365-2036.2011.04668.x. PMID: 21517924.

72. Kumar R, Rastogi A, Sharma MK, et al. 2013; Liver stiffness measurements in patients with different stages of nonalcoholic fatty liver disease: diagnostic performance and clinicopathological correlation. Dig Dis Sci. 58:265–274. DOI: 10.1007/s10620-012-2306-1. PMID: 22790906.

73. Mahadeva S, Mahfudz AS, Vijayanathan A, Goh KL, Kulenthran A, Cheah PL. 2013; Performance of transient elastography (TE) and factors associated with discordance in non-alcoholic fatty liver disease. J Dig Dis. 14:604–610. DOI: 10.1111/1751-2980.12088. PMID: 23859493.

74. Chan WK, Nik Mustapha NR, Mahadeva S. 2015; A novel 2-step approach combining the NAFLD fibrosis score and liver stiffness measurement for predicting advanced fibrosis. Hepatol Int. 9:594–602. DOI: 10.1007/s12072-014-9596-7. PMID: 25788185.

75. Anstee QM, Lawitz EJ, Alkhouri N, et al. 2019; Noninvasive tests accurately identify advanced fibrosis due to NASH: Baseline data from the STELLAR trials. Hepatology. 70:1521–1530. DOI: 10.1002/hep.30842. PMID: 31271665.

76. Boursier J, Vergniol J, Guillet A, et al. 2016; Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. J Hepatol. 65:570–578. DOI: 10.1016/j.jhep.2016.04.023. PMID: 27151181.

77. Rosso C, Caviglia GP, Abate ML, et al. 2016; Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis. Dig Liver Dis. 48:55–61. DOI: 10.1016/j.dld.2015.09.008. PMID: 26514735.

78. Lee MS, Bae JM, Joo SK, et al. 2017; Prospective comparison among transient elastography, supersonic shear imaging, and ARFI imaging for predicting fibrosis in nonalcoholic fatty liver disease. PLoS One. 12:e0188321. DOI: 10.1371/journal.pone.0188321. PMID: 29176844. PMCID: PMC5703509.

79. Garg H, Aggarwal S, Shalimar , et al. 2018; Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients. Surg Obes Relat Dis. 14:81–91. DOI: 10.1016/j.soard.2017.09.005. PMID: 29126863.

80. Furlan A, Tublin ME, Yu L, Chopra KB, Lippello A, Behari J. 2020; Comparison of 2D shear wave elastography, transient elastography, and MR elastography for the diagnosis of fibrosis in patients with nonalcoholic fatty liver disease. AJR Am J Roentgenol. 214:W20–W26. DOI: 10.2214/AJR.19.21267. PMID: 31714842.

81. Lee DH, Sung SU, Lee YK, et al. 2022; A sequential approach using the age-adjusted fibrosis-4 index and vibration-controlled transient elastography to detect advanced fibrosis in Korean patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 55:994–1007. DOI: 10.1111/apt.16766. PMID: 35005800.